ASLN - アスラン・ファ―マシュ―ティカルズ （ASLAN Pharmaceuticals Limited） アスラン・ファ―マシュ―ティカルズASLNのチャート
ASLNの企業情報
| symbol | ASLN |
|---|---|
| 会社名 | ASLAN Pharmaceuticals Ltd （アスラン・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | ― 医療関連（Health Care） |
| 概要 | 事業概要 -- アスラン・ファ―マシュ―ティカルズはケイマン諸島籍のバイオ医薬品メ―カ―。臨床段階で腫瘍学を中心に、アジアで一般的な疾病や、欧米での希少疾病を対象とした治療薬の開発を手掛ける。胆道がん、胃がん、乳がん、結腸直腸がん、急性骨髄性白血病、喘息、アトピ―性皮膚炎などの候補薬を保有する。台湾、オ―ストラリア、中国に事務所を置く。本社所在地はシンガポ―ル。 ASLAN Pharmaceuticals, a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Kathleen M. Metters, PhD, as an independent director. Dr Metters has more than 30 years’ experience in the discovery and development of novel therapies for the treatment of chronic diseases, including autoimmune diseases. Dr Metters is a member of several boards, including Hemoshear Therapeutics LLC and Pharmaxis Ltd (ASX:PSX). Most recently, she was Chief Executive Officer and President of Lycera Corp, where she spearheaded a robust pipeline of proprietary and partnered immune modulator programs. |
| 本社所在地 | 190 Elgin Avenue George Town Grand Cayman KY1-9005 CYM |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | 41791 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | 38人 |
| url | www.aslanpharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/asln |
| adr_tso | 6000000 |
| EBITDA | EBITDA ー |
| 終値（lastsale） | 7.32 |
| 時価総額（marketcap） | 43920000 |
| 時価総額 | 時価総額 ― |
| 売上高 | 売上高 -- |
| 企業価値(EV) | 企業価値(EV) ー |
| 当期純利益 | 当期純利益 -- |
| 決算概要 | 決算概要 -- |
ASLNのテクニカル分析
ASLNのニュース
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday''s Mid-Day Session 2023/01/04 18:17:01 Benzinga
Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS ) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sleep apnea. Crown ElectroKinetics Corp. (NASDAQ: CRKN ) climbed 162% to $0.4909 after the company announced it acquired Amerigen 7. Cryptyde, Inc. (NASDAQ: TYDE ) gained 108% to $0.4022. Geron Corporation (NASDAQ: GERN ) shares jumped 53.3% to $3.6800 after the company announced top-line results from the IMerge Phase 3 trial of imetelstat in lower risk MDS. The trial met the primary 8-week transfusion independence (TI) endpoint and key secondary 24-week TI endpoint. Shift Technologies, Inc. (NASDAQ: SFT ) rose 49% to $0.2350. Neptune Wellness Solutions Inc. (NASDAQ: NEPT ) jumped 42.4% to $0.4132. The company earlier reported in 13G filing Sabby Volatility Warrant Master Fund held 11% stake in Neptune Wellness Solutions. Reunion Neuroscience Inc. (NASDAQ: REUN ) gained 27.8% to $1.33. Armata Pharmaceuticals, Inc. (NASDAQ: ARMP ) surged 25% to $ 1.3799.
ASLAN, Thermo Fisher Join To Manufacture High Concentration Formulation Of Eblasakimab 2023/01/03 12:42:00 Finanz Nachrichten
SINGAPUR (dpa-AFX) - ASLAN Pharmaceuticals (ASLN) and Thermo Fisher Scientific Inc (TMO) announced a partnership to manufacture a high concentration formulation of eblasakimab for Phase 3 clinical…
Aslan, Thermo Fisher team up to make eblasakimab for clinical trials 2023/01/03 12:40:10 Seeking Alpha
Aslan Pharmaceuticals (ASLN) said it is collaborating with Thermo Fisher Scientific (TMO) to manufacture a high concentration formulation of eblasakimab for phase 3 trials.Aslan said…
ASLAN Pharmaceuticals and Thermo Fisher Scientific Announce Partnership to Manufacture High Concentration Formulation of Eblasakimab for Future Studies 2023/01/03 12:00:00 GlobeNewswire
SAN MATEO, Calif. and SINGAPORE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, and Thermo Fisher Scientific Inc (NYSE: TMO), the world leader in serving science, today announced a partnership to manufacture a high concentration formulation of eblasakimab for Phase 3 clinical trials. Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor that has the potential to deliver a differentiated efficacy and safety profile for the treatment of moderate-to-severe atopic dermatitis (AD).
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences | MarketScreener 2022/12/16 12:47:03 MarketScreener
SAN MATEO, Calif. and SINGAPORE, Dec. 16, 2022 -- ASLAN Pharmaceuticals , a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of… | December 16, 2022
ASLAN Pharmaceuticals to Participate in a Fireside Chat at 34th Annual Piper Sandler Healthcare Conference 2022/11/21 12:00:00 GlobeNewswire
SAN MATEO, Calif. and SINGAPORE, Nov. 21, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to participate in a fireside chat at the Piper Sandler Healthcare Conference on Thursday, December 1, 2022, at 8:30am ET. The conference will be held from November 29 to December 1, 2022, in-person at the Lotte New York Palace Hotel, New York, NY.
ASLAN Pharmaceuticals to Participate in Jefferies London Healthcare Conference 2022/11/08 12:00:00 GlobeNewswire
SAN MATEO, Calif. and SINGAPORE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, and Mr Stephen Doyle, CBO will be participating in one-on-one meetings at the Jefferies London Healthcare Conference from November 15 to 17, 2022. The conference will be held in-person at the Waldorf Hilton hotel in London.
Weak Fundamental Momentum Pushes ASLAN Pharmaceuticals Limited (ASLN) Lower 2022/11/02 16:20:00 Marketing Sentinel
ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) has a beta value of 1.50 and has seen 0.96 million shares traded in the recent trading session. The company, currently valued at $26.06M, closed the recent trade at $0.37 per share which meant it lost -$0.01 on the day or -1.33% during that session. The ASLN stock price is -416.22% … Weak Fundamental Momentum Pushes ASLAN Pharmaceuticals Limited (ASLN) Lower Read More »
ASLAN Pharmaceuticals GAAP EPS of -$0.02 2022/10/28 11:29:31 Seeking Alpha
ASLAN Pharmaceuticals press release (ASLN): Q3 GAAP EPS of -$0.02.Company maintains healthy operating position with $68.9 million in cash, cash equivalents and short-term investments…
ASLAN Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update 2022/10/28 11:00:00 GlobeNewswire
SAN MATEO, Calif. and SINGAPORE, Oct. 28, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the third quarter ended September 30, 2022, and provided an update on recent corporate activities.
Recap: ASLAN Pharmaceuticals Q4 Earnings 2022/03/25 11:47:55 Benzinga
ASLAN Pharmaceuticals (NASDAQ: ASLN ) reported its Q4 earnings results on Friday, March 25, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings ASLAN Pharmaceuticals missed estimated earnings by 14.29%, reporting an EPS of … Full story available on Benzinga.com
ASLAN Pharmaceuticals GAAP EPS of -$0.03 2022/03/25 11:24:30 Seeking Alpha
ASLAN Pharmaceuticals press release (ASLN): Q4 GAAP EPS of -$0.03.Cash and cash equivalents of $90.2M as of December 31, 2021Shares +1.15% PM.
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update 2022/03/25 11:00:00 GlobeNewswire
MENLO PARK, Calif. and SINGAPORE, March 25, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fourth quarter and full year ended December 31, 2021, and provided an update on recent corporate activities.
ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab Proof-of-Concept Study in Atopic Dermatitis for Oral Presentation at the 2022 American Academy of Dermatology Annual Meeting 2022/03/18 11:00:00 Benzinga
- Topline data from the eblasakimab Phase 1b multiple-ascending-dose study will be presented during the "Late-breaking Research: Clinical Trials" session at the 2022 American Academy of Dermatology Annual Meeting on March 26 MENLO PARK, Calif. and SINGAPORE, March 18, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN ), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that an abstract highlighting key efficacy and safety data from the completed Phase 1b study for eblasakimab (ASLAN004) in atopic dermatitis (AD) has been accepted for late-breaking oral presentation at the 2022 American Academy of Dermatology Annual Meeting, to be held in-person March … Full story available on Benzinga.com